Advances in understanding the role of type i interferons in systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 26, Issue 5, 2014, Pages 467-474

  Crow, Mary K ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

autoimmunity; cytoplasmic sensors; interferon ; long interspersed nuclear elements; systemic lupus erythematosus; Toll like receptors; type I interferons

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON ANTIBODY; AUTOANTIBODY; BETA INTERFERON; CYTOKINE ANTIBODY; CYTOPLASMIC RECEPTOR; DNA; HYDROXYCHLOROQUINE; INTERFERON; INTERFERON REGULATORY FACTOR 5; NUCLEIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; RNA; RNA BINDING PROTEIN; SIFALIMUMAB; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNITY; CELL TYPE; CYTOKINE PRODUCTION; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; HUMAN; IMMUNE DYSREGULATION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NEUTROPHIL; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; ULTRAVIOLET RADIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MOUSE;

ANIMALS; AUTOIMMUNITY; GENETIC ASSOCIATION STUDIES; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MODELS, IMMUNOLOGICAL; NEUTROPHILS; RECEPTOR, INTERFERON ALPHA-BETA; TOLL-LIKE RECEPTORS;

EID: 84905456707     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000087     Document Type: Review

References (72)

1. Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis 2013; 72 (Suppl. 2):ii56-ii61.
2. Ghodke-Puranik Y, Niewold TB. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int J Clin Rheumtol 2013; 8:657-669.
3. Cherian TS, Kariuki SN, Franek BS, et al. Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum 2012; 64:3383-3387.
4. Rice GI, Forte GM, Szynkiewicz M, et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol 2013; 12:1159-1169.
5. Lee-Kirsch MA, Wolf C, Gunther C. Aicardi-Goutieres syndrome: a model disease for systemic autoimmunity. Clin Exp Immunol 2014; 175:17-24.
6. Rice GI, Kasher PR, Forte GM, et al. Mutations in ADAR1 cause Aicardi- Goutieres syndrome associated with a type I interferon signature. Nat Genet 2012; 44:1243-1248.
7. Orebaugh CD, Fye JM, Harvey S, et al. The TREX1 C-terminal region controls cellular localization through ubiquitination. J Biol Chem 2013; 288:28881-28892.
8. Coit P, Jeffries M, Altorok N, et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferonregulated genes in naive CD4+ T cells from lupus patients. J Autoimmun 2013; 43:78-84.
9. Absher DM, Li X, Waite LL, et al. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet 2013; 9:e1003678.
10. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003; 36:481-490.
11. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009; 2009:1-16.
12. Bloom CI, Graham CM, Berry MP, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 2013; 8:e70630.
13. Chiche L, Jourde-Chiche N, Pascual V, Chaussabel D. Current perspectives on systems immunology approaches to rheumatic diseases. Arthritis Rheum 2013; 65:1407-1417.
14. Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014; 66:1583-1595.
15. De Weerd NA, Vivian JP, Nguyen TK, et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat Immunol 2013; 14:901-907.
16. Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci USA 2012; 109:17609-17614.
17. Baccala R, Gonzalez-Quintial R, Blasius AL, et al. Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus. Proc Natl Acad Sci USA 2013; 110:2940-2945.
18. Gall A, Treuting P, Elkon KB, et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012; 36:120-131.
19. Kaplan MJ. Role of neutrophils in systemic autoimmune diseases. Arthritis Res Ther 2013; 15:219.
20. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011; 3:73ra20.
21. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011; 3:73ra19.
22. Ries M, Schuster P, Thomann S, et al. Identification of novel oligonucleotides from mitochondrial DNA that spontaneously induce plasmacytoid dendritic cell activation. J Leukoc Biol 2013; 94:123-135.
23. Denny MF, Yalavarthi S, Zhao W, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010; 184:3284-3297.
24. Palanichamy A, Bauer JW, Yalavarthi S, et al. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. J Immunol 2014; 192:906-918.
25. Campbell AM, Kashgarian M, Shlomchik MJ. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci Transl Med 2012; 4:157ra141.
26. Shrivastav M, Niewold TB. Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol 2013; 4:319.
27. Hasan M, Yan N. Safeguard against DNA sensing: the role of TREX1 in HIV-1 infection and autoimmune diseases. Front Microbiol 2014; 5:193.
28. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 2014; 32:461-488.
29. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Annu Rev Immunol 2011; 29:185-214.
30. Crampton SP, Bolland S. Spontaneous activation of RNA-sensing pathways in autoimmune disease. Curr Opin Immunol 2013; 25:712-719.
31. Ma Z, Moore R, Xu X, Barber GN. DDX24 negatively regulates cytosolic RNAmediated innate immune signaling. PLoS Pathog 2013; 9:e1003721.
32. Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013; 339:786-791.
33. Wu J, Sun L, Chen X, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013; 339:826-830.
34. Diner EJ, Burdette DL, Wilson SC, et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 2013; 3:1355-1361.
35. Ablasser A, Goldeck M, Cavlar T, et al. cGAS produces a 20-50-linked cyclic dinucleotide second messenger that activates STING. Nature 2013; 498:380-384.
36. Civril F, Deimling T, de Oliveira Mann CC, et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature 2013; 498:332-337.
37. Barber GN. STING-dependent cytosolic DNA sensing pathways. Trends Immunol 2013; 35:88-93.
38. Lazear HM, Lancaster A, Wilkins C, et al. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 2013; 9:e1003118.
39. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008; 134:587-598.
40. Stetson DB. Endogenous retroelements and autoimmune disease. Curr Opin Immunol 2012; 24:692-697.
41. Volkman HE, Stetson DB. The enemy within: endogenous retroelements and autoimmune disease. Nat Immunol 2014; 15:415-422.
42. Crow MK. Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease. Autoimmunity 2010; 43:7-16.
43. Behrendt R, Schumann T, Gerbaulet A, et al. Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response. Cell Rep 2013; 4:689-696.
44. Zhao K, Du J, Han X, et al. Modulation of LINE-1 and Alu/SVA retrotransposition by Aicardi-Goutieres syndrome-related SAMHD1. Cell Rep 2013; 4:1108-1115.
45. Kretschmer S, Wolf C, Konig N, et al. SAMHD1 prevents autoimmunity by maintaining genome stability. Ann Rheum Dis 2014. [Epub ahead of print]
46. Gehrke N, Mertens C, Zillinger T, et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STINGdependent immune sensing. Immunity 2013; 39:482-495.
47. Kono DH, Baccala R, Theofilopoulos AN. TLRs and interferons: a central paradigm in autoimmunity. Curr Opin Immunol 2013; 25:720-727.
48. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52:1491-1503.
49. Henault J, Martinez J, Riggs JM, et al. Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. Immunity 2012; 37:986-997.
50. Guiducci C, Gong M, Cepika AM, et al. RNA recognition by human TLR8 can lead to autoimmune inflammation. J Exp Med 2013; 210:2903-2919.
51. Kyogoku C, Smiljanovic B, Grun JR, et al. Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference? PLoS One 2013; 8:e83776.
52. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013; 340:202-207.
53. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013; 340:207-211.
54. Hardy GA, Sieg S, Rodriguez B, et al. Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One 2013; 8:e56527.
55. Abeler-Dorner L, Rieger CC, Berger B, et al. Interferon-alpha abrogates the suppressive effect of apoptotic cells on dendritic cells in an in vitro model of systemic lupus erythematosus pathogenesis. J Rheumatol 2013; 40:1683-1696.
56. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12:125-135.
57. Migliorini A, Angelotti ML, Mulay SR, et al. The antiviral cytokines IFN-alpha and IFN-beta modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am J Pathol 2013; 183:431-440.
58. Knight JS, Kaplan MJ. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol 2013; 25:597-605.
59. Duffau P, Seneschal J, Nicco C, et al. Platelet CD154 potentiates interferonalpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med 2010; 2:47ra63.
60. Somers EC, Zhao W, Lewis EE, et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012; 7:e37000.
61. Stohl W. Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol 2013; 9:705-720.
62. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human antiinterferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011; 70:1905-1913.
63. McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012; 64:3666-3676.
64. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ betainducible genes and downstream effect in a phase I trial of an antiinterferonalpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1785-1796.
65. Wang B, Higgs BW, Chang L, et al. Pharmacogenomics and translational simulations to bridge indications for an antiinterferon-alpha receptor antibody. Clin Pharmacol Ther 2013; 93:483-492.
66. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008; 223:271-283.
67. Kandimalla ER, Bhagat L, Wang D, et al. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res 2013; 41:3947-3961.
68. Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum 2013; 65:447-456.
69. Sun X, Wiedeman A, Agrawal N, et al. Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J Immunol 2013; 190:2536-2543.
70. Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012; 14:R155.
71. Kirou KA, Gkrouzman E. Antiinterferon alpha treatment in SLE. Clin Immunol 2013; 148:303-312.
72. Ferreira RC, Guo H, Coulson RM, et al. A type I interferon transcriptional signature precedes autoimmunity in children genetically at-risk of type 1 diabetes. Diabetes 2014. [Epub ahead of print]